Lupin Wins Court Ruling That Its Generic Kalydeco Does Not Infringe Vertex Cystic Fibrosis Patents
Key Takeaways
- •A US federal judge ruled that Lupin's generic version of Kalydeco does not infringe four Vertex Pharmaceuticals patents for the cystic fibrosis treatment.
- •The court found that Vertex's use of the vague term 'about 80%' for the active ingredient concentration weighed against a finding of infringement.
- •Kalydeco, approved by the FDA in 2012, was the first medicine to target the underlying cause of cystic fibrosis rather than its symptoms.
- •The ruling removes a legal obstacle for Lupin, but the company still needs regulatory approval before marketing its generic in the US.
- •The decision may lead to closer scrutiny of qualitative terms like 'about' in future pharmaceutical formulation patents.
A federal judge in the United States has ruled that Lupin's generic version of Kalydeco does not infringe four Vertex Pharmaceuticals patents covering the cystic fibrosis treatment, handing the Indian drugmaker a favorable outcome in the long-running patent dispute.
The court's decision turned on the wording of Vertex's patent claims. The judge found that Vertex's use of the term "about 80%" to describe the concentration of the drug's active ingredient was vague, and that this vagueness weighed against a finding of infringement by Lupin's proposed generic product.
Kalydeco (ivacaftor), developed by Vertex Pharmaceuticals, was approved by the US Food and Drug Administration in 2012 as the first medicine to target the underlying cause of cystic fibrosis rather than just its symptoms. It is approved for patients with specific mutations in the CFTR gene, which cause the faulty protein responsible for the disease. Vertex has built a portfolio of CF treatments around this mechanism, and generics of these drugs have historically faced significant patent barriers in the US market, one reason CF medicines remain among the most expensive therapies for patients and insurers.
The ruling removes one legal obstacle for Lupin as it pursues approval of its generic Kalydeco in the United States, though the company would still need regulatory approval for its product. Patent litigation between brand-name and generic manufacturers is a common feature of the US pharmaceutical industry under the Hatch-Waxman framework, where generic applicants that challenge patents in court can, if successful, gain periods of marketing exclusivity, and such cases often determine when lower-cost generic versions can reach patients.
The dispute centered on Vertex patents asserting specific concentration ranges for the formulation, with Lupin arguing its product fell outside the protected scope. The court's reliance on the imprecision of the "about 80%" claim highlights how the exact wording of patent claims can determine the outcome of pharmaceutical infringement cases, and drafters of future formulation patents may face closer scrutiny of qualitative terms like "about" as a result of this reasoning in similar disputes.
Source: CNBC-TV18
